full list rate price target
earn chang report pleas see
tabl page
though sentiment across biopharma challeng rhetor drug
price industri fundament still good evidenc solid earn
season backdrop posit new launch still earli inning alexion
ultomiri gilead biktarvi abbvi skyrizi de-risk pipelin asset horizon
vertex tripl combo celgen ozanimod activ pick bmy-celg
support posit outlook despit industri lag market ytd
drg nbi drug price concern risk
overhang go elect today market
weak smid cap biotech hit harder
late within group wed point orphan space area opportun
compani emerg portfolio diversif
give updat group earn season discuss rate
chang host call today et us
ou passcod reassess sector
updat rate pt univers see bodi note detail
bristol upgrad overweight ew revis pt
bullish bristol share given increas confid celgen
deal success close follow favor sharehold vote last month
recogn controversi surround propos deal revlimid eros
think combin compani look attract current level given
increas option celgen pipelin importantli differenti
growth profile/earn power next year
celgen celg downgrad equal weight ow pt unchang
increas probabl deal close downgrad celgen
ew thesi larg play remain posit cvr
probabl given good clinical/regulatori progress ozanimod
downgrad equal weight ow revis pt
though posit jakafi franchis dont see new valuat
inflect point gvhd opportun pemagatinib earli stage pipelin
especi share alreadi ytd nbi index weve note
think narrow scope earlier pipelin
disciplin approach invest would strateg posit
rate chang price target revis downgrad acceleron ew
ow pt limit upsid opportun given alreadi high
expect luspatercept downgrad achillion uw ew pt
limit data regulatori clariti newest iter factor program
also rais price target maintain ew follow
strong perform favor overal outlook
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
bristol-my upgrad overweight
bristol-my squibb quarterli annual ep usd
consensu number refinitiv receiv gmt
upgrad overweight pt
chang view upgrad share overweight rais
price target increas confid propos celgen
acquisit close later year back last month favor sharehold vote
recogn appar risk come propos deal revlimid erosion/ip
risk clinic commerci risk late-stag pipelin asset think combin
compani attract near longer term provid bristol much-need
optionalitywith wed character strong fairli de-risk pipelin
celgeneand dramat differenti growth profil look see figur
pro forma assumpt barclay pf model/rec slide analysi
wouldnt surpris see multipl expand sever turn de-risk
catalyst play cours year like data/regulatori submiss
bullish outlook root success launch trajectori
late-stag asset note outlook could impact asset
respect i/o franchis remain view merck maintain
leadership posit across space particularli lung rcc said
see upsid opportun lung get updat summerwith
market current ascrib littl lung valu share analysi
potenti impact near-term readout see bristol-my squibb
risk/reward ahead
valuat revis price target vs prior deriv blend averag
price/growth multipl prior base larg cap global therapeut
group view appropri given primari focu specialti
drug/biotechnology-ori compani discount cash flow valu
prior analysi assign equal weight two methodolog deriv
price target per share
risk rate initi launch addit data pipelin asset
celgen bristol underwhelm could see weak share
addit see littl room downsid lung given share
current trade meaning share contract key market like lung
rcc current expect could pressur bristol overal posit i/o
barclay research refinitiv data march
barclay research refinitiv data march
celgen downgrad equal weight
celgen corp celg quarterli annual ep usd
consensu number refinitiv receiv gmt
downgrad equal weight maintain pt
chang view downgrad share equal weight
maintain pt follow recent bristol sharehold vote favor deal
still high convict deal close think current share
level thesi larg play emerg focu cvr wed
character increasingli de-risk ozanimod progress
clinic regulatori front maintain posit view deal overal believ
combin compani repres much attract invest opportun
either two stand-alon entiti
valuat price target base price-to-earnings multipl support sum-
of-th part npv analysi use wacc base busi assign
revlimid pom/ thal/ vidaza otezla abraxan
pipelin assign luspatercept ozanimod
combin equity/ platform valu net cash support pt
risk rate think much risk mitig point
still downsid risk deal goe throughwhich could bring share
substanti like high rang
downgrad equal weight
corp quarterli annual ep usd
consensu number refinitiv receiv gmt
downgrad equal weight pt
chang view long posit given option
pipelin inde major share trade larg
basi jakafi jakavi/ olumi royalti net cash minim valu ascrib
pipelin share experienc strong ytd vs nbi wed
argu less reflect commerci outlook upsid late-stag
pipelin due overal backdrop smid cap biotech much
slower pipelin progress believ manag increasingli
large/divers develop portfolio especi earlier stage asset rather
argu could unlock signific valu reduc overal spend refocus
develop effort later-stag asset strateg align
greater synergi current portfolio spin off/split remaind
see corp dear manag board
discuss recent earn call clear effort improv
financi disciplin includ decis discontinu co-develop
baricitinib lilli make sens given competit dynam
continu strengthen argument ad valu share price
ruxolitinib cream advanc phase remain question strateg fit
stand would anti market see corp
thought call continu see strength core
busi adjust forecast jakafi number roughli
line consensu vs con
well late stage pipelin itacitinib treatment-nav acut gvhd
pemigatinib cholangiocarcinoma well-posit launch next year
recogn option remain pipelin parsaclisib especi
launch fgfr inhibitor balversa like compet pemigatinib
bladder cancer believ would better serv adjust development focu
thu downgrad rate equal weight
valuat price target prior base sum-of-the-part npv analysi
use updat discount rate vs prior probabl adjust
appropri base deriv valu jakafi vs
prior baricitinib royalti net cash vs
prior broader pipelin net cash
risk rate develop earli stage pipelin axl/mer
arg gitr pim proce much rapidli
discontinuing/out-licens major progress forward asset
support good clinic data commerci strateg rational
acceleron downgrad equal weight
quarterli annual ep usd
consensu number refinitiv receiv gmt
downgrad equal weight pt
street
vs
chang view remain bullish luspatercept particularli earli
launch phase expect pick share begin drive sale remain
moder
consensu howev de-risk high profil asset
tout celgen bristol meaning contributor econom
acquisit luspatercept potenti well-recogn market view leav
limit room upsid point think luspatercept support current
valuat would prefer remain side-lin confid build
earlier stage pipelin abil drive anoth leg growth beyond luspatercept
valuat revis price target base npv analysi forecast risk
adjust sale luspatercept treatment myelodysplast syndrom beta-
thalassemia sale begin end well sotatercept
chronic kidney diseas pulmonari arteri hypertens sale begin
end
facioscapulohumer muscular dystrophi fshd start end
given assumpt deriv valuat luspatercept
sotatercept net
cash unchang remov discontinu
program result npv support price target
also
could wrong luspatercept get market earlier base case
assumpt earli stock could react posit above-consensu earli
launch could likewis drive upsid addit except data earlier pipelin asset
addit luspatercept indic like myelofibrosi could caus
investor rais assumpt probabl success increas valu stock
achillion downgrad underweight
achn quarterli annual ep usd
consensu number refinitiv receiv gmt
downgrad underweight pt
chang view downgrad share achillion underweight
equal weight reduc pt note achn share
rebound quit nice yearli low seen decemb vs nbi
index share trade cash time achillion seen
substanti vs xbi run start year compani continu progress
pipelin inde achillion initi phase multiple-ascend dose studi ach-
januari potenti support submiss ind
note phase trial patient glomerulopathi recent achiev
threshold enrol begin april day compani announc
enrol complet phase pnh combin trial solirisboth trial
target end phase fda meet recogn pnh competitor
ultomiri uptak robust thu far alexion plan convert soliri
patient believ quit achiev due favor safeti efficaci
price dynam glomerulonephr note achillion face competit
landscap
inhibitor apelli
well number uniqu approach believ could
upsid program thu rate downgrad price target chang
reflect lack near- mid-term data catalyst capabl chang stori
stock less due underli long-term fundament factor program
includ complement pathway
valuat revis vs prior per share price target reflect sum-of-the-
part analysi impli intrins valu per share vs prior
pipelin asset per share unchang net cash
could wrong achillion expect disclos interim data readout month
pnh combin studi soliri dont anticip
surpris data exceed expect show sign addit upsid potenti
would certainli room stock increas meaning result
johnson johnson quarterli annual ep usd
consensu number refinitiv receiv gmt
rais pt maintain equal weight
rais price target share base strong commerci perform
favor outlook sentiment continu increas across
broader healthcar space see room multipl expansionespeci get
closer wed character achiev outlook think
share may see posit momentum enter back half year
narr shift growth stori driven uptick pharma growth said
slower organ pharma growth meaning pipelin event
come month maintain equal weight outlook figur figur
detail model updat
valuat revis price target reflect blend averag
compar analysi base appli current year price-to-earnings multipl vs
prior forward year earn vs prior sum-of-the-part analysi
use pharma med tech consum peer forward year price-to-earnings multipl give
valu vs prior discount cash flow analysi give valu
vs prior assign equal weight three methodolog
deriv price target per share
equal weight acceleron leader tgf-beta
biolog lead asset luspatercept partner
celgen blockbust potenti peak
sale estim low-risk md beta
think market expect luspatercept
reflect stock leav limit room upsid
phase data support luspatercept durat
therapi beyond month earlier stage asset
becom de-risk increasingli addit
luspatercept safeti long-term efficaci rais
question durat therapi sotatercept
muscl program fail improv standard
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight achillion restructur away
hcv becom orphan-focus compani
still need derisk clincial data
posit see lack stock-mov catalyst
near term
posit data factor program
neg clinic data factor program
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight expect leader
immuno-oncolog underwhelm
penetr lung cancer addit
near-term revlimid cash flow celgen
acquisit well late-stag pipelin see
upsid case assum posit os
part adopt tmb
faster uptak opdivo yervoy regimen
clinic success next gen i-o asset
contribut revenu celgen pipelin
downsid case assum addit headwind
front line lung set contract lung
clinical/regulatori setback reduc market
share indic like rcc
believ would drive contract multipl
equal weight believ acquisit
bristol highli like complet agre
upsid case support recent
announc bristol deal
bristol acquisit fall celgen
continu independ compani without
take-over premium stock
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight compel mix
grow commerci asset interest pipelin
asset exclud epacadostat also expect
jakafi peak royalti
howev think compani would benefit
focus approach invest
ww compel commerci perform
success earlier pipelin asset across portfolio
assum slower jakafi growth mf pf littl
uptak gvhd et similar minim
penetr olumi ra pipelin
assum failur pipelin agent itacitinib
pemigatinib
equal weight continu like jnj
continu innov bode well
longer term sentiment could remain neg
given backdrop price pressures/lo
fundament think could
challeng year particularli pharma given multipl
gener launch zytiga revenu growth
expect trough
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmaceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
valuat methodolog risk
valuat methodolog pt base sum-of-the-part analysi driven primarili luspatercept valu
sotatercept muscl program valu net cash
risk may imped achiev barclay research valuat price clinic develop risk acceleron
lead asset luspatercept evalu seri pivot studi myelodysplast syndrom md beta-thalassemia
studi fail deliv clinic meaning result delay read-out share could neg impact
addit studi elucid new advers event drug potenti indic diseas could halt
partner risk luspatercept sotatercept partner celgen world-wide basi celgen unabl success execut
clinic commerci develop agent return right drug share would like impair
compani would like requir addit financ launch either product advanc pipelin addit
celgen decid pursu phase sotatercept chronic kidney diseas may difficult acceleron advanc program
find new partner
-thalassemia md drug use patient
commerci risk celgen develop luspatercept lower risk md
longer never sensit epogen goal delay time reduc frequenc red blood cell transplant
guarante celgen success posit product posit lead meaning sale
competit risk acceleron face meaning competit number area develop drug includ muscular dystrophi
guarante acceleron abl compet agent compani may better clinic data and/or
greater resourc experi acceleron effect compet area stock may neg impact
valuat methodolog price target achn base sum-of-th part npv analysi deriv valu base
compani cash posit also deriv valu compani pipelin primarili consist factor complement
inhibitor phase pnh next- gener result pt
risk may imped achiev barclay research valuat price clinic risk achillion pipelin factor
inhibitor may success sever potenti clinic complement inhibitor demonstr minim efficaci note
potenti safeti signal phase moreov complement base diseas rare may issu
recruit patient clinic studi especi given efficaci alexion soliri commerci avail alexion also recruit
patient studi next-gener soliri impact avail patient pool
regulatori risk assum posit phase data factor inhibitor next step would regulatori file howev guarante
fda ema grant approv regimen delay approv inabl gain approv would result signific pressur
commerci risk achillion focus develop treatment complement-bas diseas howev pnh competit
market domin alexion soliri commerci avail time given alexion experi physician comfort
soliri even soliri indic gain meaning market share could challeng sale could
financi risk current cash expect support oper howev compani continu burn cash achillion
may need rais capit futur could dilut sharehold
valuat methodolog valu use blend averag price/growth basi base averag larg cap global
therapeut group view appropri given primari focu specialti drug/biotechnology-ori compani
discount cash flow analysi assign equal weight two methodolog deriv price target per share
risk may imped achiev barclay research valuat price growth prospect increasingli
depend deliveri immuno-oncolog pipelin setback delay could pose risk stock field immuno-oncolog
get increasingli competit bristol leadership challeng major player particularli merck keytruda
competit disadvantag term clinic develop regulatori timelin could put pressur stock
valuat methodolog price target base price-to-earnings multipl support sum-of-th part npv analysi use
wacc base busi assign revlimid pom/ thal/ vidaza otezla abraxan
pipelin assign luspatercept ozanimod combin equity/ platform valu
ye net cash support pt
risk may imped achiev barclay research valuat price commerci risk increas preval
mm revlimid strong competit posit provid signific tailwind could drive upsid forecast reimburs risk
mani product biotech industri high price point celgen product includ revlimid differ
surpris certain region select payor segment pushback cost decis made use less
expens treatment altern increas adopt strategi could neg impact celgen oper perform share
price clinic risk celgen deep pipelin drug candid intern partner compani develop across
rang diseas mani drug early-to-mid stage develop could fail meet target endpoint trial
fail demonstr meaning clinic benefit outcom could put impair celgen abil launch new drug could pressur
share perform litig patent risk patent relat celgen key product revlimid focu on-going litig
valuat methodolog risk
could lead market entri gener revlimid prior compani expect gener revlimid enter market prior street
expect revlimid sale could fall celgen share would neg impact gener celgen reli patent protect
invest drug develop gener entrant celgen brand product could harm futur sale regulatori risk celgen
broad pipelin could result posit late stage data howev posit data guarante fda ema grant approv
delay timelin inabl gain approv could significantli impact celgen futur sale
valuat methodolog price target base sum-of-the-part npv analysi forecast sale patent expiri key
product jakafi baricitinib assum zero termin valu use discount rate probabl adjust
appropri base deriv valu jakafi baricitinib royalti net cash
broader pipelin
risk may imped achiev barclay research valuat price commerci risk jakafi
approv therapi sale growth within myelofibrosi mf recent approv polycythemia vera pv indic critic
compani particularli pipelin begin contribut revenu slower expect launch pv plateau mf sale
would neg impact share similarli entitl royalti novarti jakafi ou sale well
baricitinib sale disappoint result either product could pressur share
clinic develop risk valuat deriv potenti futur sale pipelin asset may
success clinic trial could experi materi delay could neg impact share
price risk sell therapeut competit space could face price pressur ww could neg impact revenu
earn
competit risk face competit pressur key valu driver jakafi baricitinib emerg therapi surpass
clinic benefit demonstr agent compani project revenu stream may affect potenti affect
compani growth profil turn share
partner risk partner novarti ou right jakavi well world-wide basi baricitinib either
partner unabl success execut commerci size share could neg impact
valuat methodolog price target reflect blend averag compar analysi base appli current year price-to-earnings
multipl forward year earn sum-of-the-part analysi use pharma med tech consum peer forward year price-to-earnings multipl
risk may imped achiev barclay research valuat price upsid risk thesi moder
impact drug price healthcar reform deploy balanc sheet find growth asset better expect clinic commerci
success pipelin asset market rotat defens stock downsid risk pressur biosimilar remicade/zytiga
pipelin failur slow medic devic util lower consum spend rotat defens stock could exert downward
geoff meacham ph kristen stewart cfa herebi certifi view express research report accur reflect
person view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
